Hyperthermic intraperitoneal chemotherapy procedure for uterine sarcoma following a COVID-19 infection—case report

In the current context of COVID-19 pandemic, major oncologic surgery sometimes had to be postponed for fear overcrowding intensive care units, risk cross-contamination or severe morbidity and mortality associated witha perioperative infection. this setting, we want present first case a patient who received hyperthermic intraperitoneal chemotherapy (HIPEC) procedure uterine sarcoma following To date, is in good condition has not developed any postoperative complications.